Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/30/2025

Management of Uncontrolled Asthma

Introduction to Asthma Management

  • The American College of Physicians recommends initiating a low-dose inhaled corticosteroid (ICS) immediately for patients with persistent asthma, as this treatment is considered the foundation of asthma management 1, 2, 3
  • Using a short-acting beta-agonist (SABA) alone without anti-inflammatory controller therapy leaves the underlying airway inflammation untreated, which is the fundamental pathology in asthma 1, 2
  • SABA overuse, defined as using albuterol more than 2 days per week for symptom relief, signals poor control and the need for controller therapy 1, 2, 3

Treatment Algorithm

  • The National Asthma Education and Prevention Program (NAEPP) recommends assessing asthma severity and control by determining frequency of daytime symptoms, nighttime awakenings, SABA use, and activity limitation 1, 2
  • For mild persistent asthma, the NAEPP recommends starting low-dose ICS such as fluticasone 88 mcg twice daily or budesonide 200-600 mcg daily 1, 4
  • For moderate persistent asthma, the NAEPP recommends considering either medium-dose ICS or low-dose ICS plus a long-acting beta-agonist (LABA) 1, 2

Safety Warnings

  • The FDA recommends never using LABA monotherapy, as it carries a black-box warning and must be used with concurrent ICS therapy due to increased risk of asthma-related death 1, 2, 3
  • The American Thoracic Society recommends only considering adding a LABA if the patient remains symptomatic despite adequate adherence to low-to-medium dose ICS therapy 1, 2

Monitoring and Follow-Up

  • The American Academy of Allergy, Asthma, and Immunology recommends reassessing control in 3-6 months after initiating therapy 4, 5
  • The National Asthma Education and Prevention Program (NAEPP) recommends verifying proper inhaler technique at every visit, as poor technique is a major cause of treatment failure 1, 2
  • The American College of Physicians recommends checking adherence, as concerns about long-term corticosteroid use may affect compliance 1, 2

Initiating Inhaled Corticosteroid Therapy for Uncontrolled Asthma

Rationale for Adding Anti‑Inflammatory Controller

  • Short‑acting beta‑agonists (SABAs) provide only transient relief by reversing airway obstruction and do not treat the underlying airway inflammation that drives asthma progression. 6

Risks Associated with SABA Overuse

  • Using a SABA on more than two days per week signals poor asthma control and is linked to a higher risk of severe exacerbations. 7
  • Regular albuterol use ≥ four times daily shortens the drug’s duration of action without changing its potency, potentially compromising symptom control. 8

Alternative Controller Options When Inhaled Corticosteroids Cannot Be Used

  • In patients who cannot receive an inhaled corticosteroid, a leukotriene receptor antagonist is an evidence‑based alternative controller therapy. 7

Importance of Inhaler Technique Assessment

  • Many patients demonstrate improper inhalation technique; clinicians should directly observe technique before escalating therapy to ensure effective drug delivery. 8
  • With metered‑dose inhalers, delivering 6–10 correctly performed puffs is roughly equivalent to one nebulizer treatment; two puffs are insufficient for adequate dosing. 6

Guidance for Early Step‑Up When Low‑Dose ICS Is Insufficient

  • If asthma control remains inadequate after two weeks of low‑dose inhaled corticosteroid therapy, clinicians should promptly step up treatment (e.g., increase dose or add a long‑acting beta‑agonist). 7